Ebastine
From Wikipedia, the free encyclopedia
 |
|
|
Ebastine
|
|
| Systematic (IUPAC) name | |
| 4-(4-benzhydryloxy-1-piperidyl)-1- (4-tert-butylphenyl)butan-1-one |
|
| Identifiers | |
| CAS number | |
| ATC code | R06 |
| PubChem | |
| Chemical data | |
| Formula | C32H39NO2 |
| Mol. mass | 469.658 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | Greater than 95% |
| Metabolism | Hepatic (CYP3A4-mediated), to carebastine |
| Half life | 15 to 19 hours (carebastine) |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Ebastine (trade names Kestine, Evastin, Ebastel, Aleva) is a non-sedating H1 antihistamine.
It does not penetrate the blood-brain barrier and thus allows an effective block of the H1 receptor in peripheral tissue without a central side effect, i.e not causing sedation or drowsiness.
The basic patent for ebasine in Europe is EP-B-134124. It is often provided in micronised form, due to poor water solubility.
[edit] External links
- KESTINE Package Insert. South African Electronic Package Inserts (October 24, 1997). Retrieved on 2007-04-01.
|
|||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
